Thermo Fisher Scientific Inc (TMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 6,338,000 | 5,955,000 | 6,960,000 | 7,728,000 | 6,377,000 |
| Depreciation Amortization | 3,108,000 | 3,406,000 | 3,381,000 | 2,592,000 | 2,325,000 |
| Income taxes - deferred | -1,209,000 | -1,300,000 | -995,000 | -647,000 | -552,000 |
| Accounts receivable | -171,000 | -43,000 | -430,000 | -204,000 | -1,302,000 |
| Accounts payable and accrued liabilities | 212,000 | -500,000 | 648,000 | 479,000 | 59,000 |
| Other Working Capital | -379,000 | -537,000 | -1,049,000 | -1,548,000 | -395,000 |
| Other Operating Activity | 768,000 | 1,425,000 | 639,000 | 912,000 | 1,777,000 |
| Operating Cash Flow | $8,667,000 | $8,406,000 | $9,154,000 | $9,312,000 | $8,289,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,343,000 | -1,392,000 | -2,219,000 | -2,503,000 | -1,466,000 |
| Net Acquisitions | -3,132,000 | -3,660,000 | -39,000 | -19,395,000 | -38,000 |
| Purchase Of Investment | -3,396,000 | -208,000 | -52,000 | N/A | N/A |
| Sale Of Investment | 1,770,000 | 15,000 | 116,000 | N/A | N/A |
| Other Investing Activity | 260,000 | 103,000 | 35,000 | -34,000 | -6,000 |
| Investing Cash Flow | $-5,841,000 | $-5,142,000 | $-2,159,000 | $-21,932,000 | $-1,510,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 0 | 1,620,000 | 1,526,000 | 2,512,000 | 383,000 |
| Debt Issued | 1,204,000 | 5,942,000 | 3,193,000 | 18,137,000 | 3,464,000 |
| Debt Repayment | -3,607,000 | -5,782,000 | -375,000 | -11,738,000 | -710,000 |
| Common Stock Repurchased | -4,000,000 | -3,000,000 | -3,000,000 | -2,000,000 | -1,500,000 |
| Dividend Paid | -583,000 | -523,000 | -455,000 | -395,000 | -337,000 |
| Other Financing Activity | 194,000 | -1,879,000 | -3,699,000 | 65,000 | -341,000 |
| Financing Cash Flow | $-6,792,000 | $-3,622,000 | $-2,810,000 | $6,581,000 | $959,000 |
| Exchange Rate Effect | -91,000 | -82,000 | -139,000 | 194,000 | 176,000 |
| Beginning Cash Position | 8,097,000 | 8,537,000 | 4,491,000 | 10,336,000 | 2,422,000 |
| End Cash Position | 4,040,000 | 8,097,000 | 8,537,000 | 4,491,000 | 10,336,000 |
| Net Cash Flow | $-4,057,000 | $-440,000 | $4,046,000 | $-5,845,000 | $7,914,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 8,667,000 | 8,406,000 | 9,154,000 | 9,312,000 | 8,289,000 |
| Capital Expenditure | -1,400,000 | -1,479,000 | -2,243,000 | -2,523,000 | -1,474,000 |
| Free Cash Flow | 7,267,000 | 6,927,000 | 6,911,000 | 6,789,000 | 6,815,000 |